-
公开(公告)号：US20240221958A1
公开(公告)日：2024-07-04
申请号：US18557953
申请日：2022-04-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Martin Klammer , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen , Victor Johann Raul Jeger , Philipp Schuetz , Maria von Holtey
CPC classification number: G16H50/30 , G01N33/6893 , G01N33/70 , G01N33/728 , G01N33/74 , G01N2333/4703 , G01N2333/58 , G01N2333/585 , G01N2333/805 , G01N2333/91188 , G01N2800/26 , G01N2800/50
Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being PCT, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a cardiac Troponin, Creatinine, a BNP-type peptide, sTREM1, ESM-1, Haptoglobin, Heparin binding protein (HBP) and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being PCT and a second biomarker selected from the group consisting of: a cardiac Troponin, Creatinine, a BNP-type peptide, sTREM1, ESM-1, Haptoglobin, Heparin binding protein (HBP) and Aspartate aminotransferase, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号：US20240230673A1
公开(公告)日：2024-07-11
申请号：US18557895
申请日：2022-04-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/68 , G01N33/573
CPC classification number: G01N33/6893 , G01N33/573 , G01N33/6863 , G01N2333/475 , G01N2333/91188 , G01N2333/9121 , G01N2800/26
Abstract: The present invention relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being GDF-15, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being GDF-15 and a second biomarker selected from the group consisting of sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号：US20240230674A1
公开(公告)日：2024-07-11
申请号：US18558119
申请日：2022-04-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
CPC classification number: G01N33/6893 , G16H50/20 , G01N2800/26
Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being STREM1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being STREM1 and a second biomarker selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6 or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号：US20240219404A1
公开(公告)日：2024-07-04
申请号：US18557954
申请日：2022-04-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
CPC classification number: G01N33/6893 , G16H50/20 , G01N2333/91188 , G01N2800/26 , G01N2800/50
Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IGFBP7, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IGFBP7 and a second biomarker selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号：US20250035629A1
公开(公告)日：2025-01-30
申请号：US18696730
申请日：2022-09-28
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/573 , G01N33/68
Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being MR-proADM, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFlt-1, GDF15 and ESM1, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being MR-proADM and a second biomarker selected from the group consisting of: sFlt-1, GDF15 and ESM1, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号：US20240248098A1
公开(公告)日：2024-07-25
申请号：US18558098
申请日：2022-04-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
CPC classification number: G01N33/6893 , G16H50/20 , G01N2800/26 , G01N2800/50
Abstract: The present invention concerns the field of diagnostics. Specifically. it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject. said first biomarker being NGAL. determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: HBP (Heparin-binding protein). Aspartate aminotransferase. Bilirubin. Alanine aminotransferase. ESM-1 and a BNP-type peptide. comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers. and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being NGAL and a second biomarker selected from the group consisting of: HBP (Heparin-binding protein). Aspartate aminotransferase. Bilirubin. Alanine aminotransferase. ESM-1 and a BNP-type peptide. or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover. the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号：US20240230675A1
公开(公告)日：2024-07-11
申请号：US18558144
申请日：2022-04-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
CPC classification number: G01N33/6893 , C12Q1/37 , C12Q1/485 , C12Q1/52 , G01N33/70 , G01N33/728 , G16H50/30 , G01N2333/71 , G01N2333/8139 , G01N2333/91188 , G01N2333/9121 , G01N2800/26 , G01N2800/50
Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being sFlt1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, STREM1, PCT and Bilirubin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being sFltl and a second biomarker selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, sTREM1, PCT and Bilirubin, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号：US20240230676A1
公开(公告)日：2024-07-11
申请号：US18558150
申请日：2022-04-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
CPC classification number: G01N33/6893 , C12Q1/37 , C12Q1/52 , G01N33/728 , G16H50/20 , G01N2333/4722 , G01N2333/8139 , G01N2333/91188 , G01N2800/26 , G01N2800/50
Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being ESM-1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a Cystatin C, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being ESM-1 and a second biomarker being Creatinine or a Cystatin C or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号：US20240219405A1
公开(公告)日：2024-07-04
申请号：US18558133
申请日：2022-04-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
CPC classification number: G01N33/6893 , G01N33/6869 , G01N33/6887 , G01N33/70 , G01N2333/5412 , G01N2333/91188 , G01N2800/26 , G01N2800/50
Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IL-6, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a cardiac Troponin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IL-6 and a second biomarker being a cardiac Troponin or Creatinine or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
